{
  "ticker": "MDGL",
  "company_name": "Madrigal Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03413124",
      "title": "Bioavailability Study of MGL-3196 Tablets Compared to Capsules",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2018-02-05",
      "completion_date": "2018-03-13",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03900429",
      "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "NASH - Nonalcoholic Steatohepatitis",
      "start_date": "2019-03-28",
      "completion_date": "2028-01",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT07335601",
      "title": "Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "MASH - Metabolic Dysfunction-Associated Steatohepatitis",
      "start_date": "2025-12-29",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04197479",
      "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Non-Alcoholic Fatty Liver Disease",
      "start_date": "2019-12-16",
      "completion_date": "2023-01-06",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02542969",
      "title": "Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2015-09",
      "completion_date": "2015-10",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05500222",
      "title": "A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "NASH, Cirrhosis, Liver",
      "start_date": "2022-08-26",
      "completion_date": "2027-01",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04671069",
      "title": "Drug Interaction Study of MGL-3196 With Clopidogrel",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2019-07-26",
      "completion_date": "2019-09-14",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04951219",
      "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Non-Alcoholic Fatty Liver Disease",
      "start_date": "2021-07-09",
      "completion_date": "2026-04",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02912260",
      "title": "Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Non-alcoholic Steatohepatitis",
      "start_date": "2016-10-18",
      "completion_date": "2021-11-23",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02749578",
      "title": "Drug Interaction Study of MGL-3196 With Atorvastatin",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2016-04",
      "completion_date": "2016-05",
      "enrollment": 0,
      "sponsor": "Madrigal Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 17,
    "by_phase": {
      "PHASE1": 10,
      "PHASE3": 4,
      "PHASE2": 3
    },
    "by_status": {
      "COMPLETED": 13,
      "ACTIVE_NOT_RECRUITING": 4
    },
    "active_trials": 4,
    "completed_trials": 13,
    "conditions": [
      "Drug Safety",
      "Healthy",
      "Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver",
      "Heterozygous Familial Hypercholesterolemia",
      "MASH - Metabolic Dysfunction-Associated Steatohepatitis",
      "NASH - Nonalcoholic Steatohepatitis",
      "NASH, Cirrhosis, Liver",
      "Non-Alcoholic Fatty Liver Disease",
      "Non-alcoholic Steatohepatitis",
      "Renal Impairment"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:52.699789",
    "search_query": "Madrigal Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Madrigal+Pharmaceuticals,+Inc."
  }
}